Key result
Low-dose rosuvastatin is tolerated by ~89% of statin-intolerant patients, reducing LDL-C up to ~43%.
Observational (n=325)
Yes
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily dosing regimens. RESEARCH DESIGN AND METHODS: A retrospective survey was conducted at nine primary, secondary and tertiary healthcare centres in the United Kingdom. MAIN OUTCOME MEASURES: Changes in lipid fractions from baseline values after more than 3 months' treatment. RESULTS: A total of 325 patients were identified. These patients were aged 63 ± 10 years, 50% male and prescription was mostly for primary prevention of cardiovascular disease (CVD) (59%). Co-morbidities included: established CVD present in 41%, type 2 diabetes mellitus (15%), hypertension (74%) and smoking (9%). Adverse effects had been documented to simvastatin (75%) or atorvastatin (63%). A total of 289 patients (89%) tolerated rosuvastatin well and were still adherent after a median follow-up of 14.9 (3-79) months. The remainder (n = 36; 11%) discontinued the medication after median 5 months' treatment due to adverse effects. Efficacy was assessed in 224 patients who had adequate data. Baseline lipids were total cholesterol (TC) 7.41 ± 1.50 mmol/L, triglycerides (TG) 2.26 (range 0.36-18.4) mmol/L; high density lipoprotein cholesterol (HDL-C) 1.43 ± 0.47 mmol/L and low density lipoprotein cholesterol (LDL-C) 4.76 ± 1.38 mmol/L. Daily rosuvastatin (n = 134) reduced mean TC by 31%, TG 15% and LDL-C 43% (p < 0.001). Rosuvastatin 5 mg 2-3 times weekly (n = 79) reduced TC 26%, TG 16% and LDL-C 32% (p < 0.001). Weekly rosuvastatin (n = 11) reduced TC 17%, LDL-C by 23% (p < 0.001) but had no effect on TGs. Targets were attained in 17% of CHD-risk equivalent patients and 41% of primary prevention patients by National Cholesterol Education Program criteria and 27% and 68% using UK targets. No myositis or rhabdomyolysis was observed and alanine aminotransferase (ALT) and creatine kinase (CK) were similar to baseline. CONCLUSIONS: In this retrospective observational multicentre study, rosuvastatin 5 mg was found to be safe and biochemically effective either as daily or intermittent therapy in patients intolerant to other conventional statin regimens.
No takes yet. Share an insight, caveat, or question.
Meek et al. (2012) conducted an observational in Statin intolerance / Dyslipidemia (n=325). Rosuvastatin 5 mg (daily, 2-3 times weekly, or weekly) vs. Baseline lipid values was evaluated on Changes in lipid fractions (LDL-C, TC, TG) from baseline after >3 months and tolerability (p=<0.001). Rosuvastatin was tolerated by 89% of statin-intolerant patients and reduced LDL-C by 43% (daily), 32% (2-3x/week), and 23% (weekly).
Synapse has enriched 10 related papers. Consider them for comparative context: